Specify a stock or a cryptocurrency in the search bar to get a summary
Alzamend Neuro Inc
ALZNAlzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia. Address: 3480 Peachtree Road NE, Atlanta, GA, United States, 30326
Analytics
WallStreet Target Price
210 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures ALZN
Dividend Analytics ALZN
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History ALZN
Stock Valuation ALZN
Financials ALZN
Results | 2019 | Dynamics |